Use of Intravitreal Bevacizumab in Eyes With Choroidal Neovascularization Secondary to Angioid Streaks

The recruitment status of this study is unknown because the information has not been verified recently.

Verified January 2008 by Asociación para Evitar la Ceguera en México.
Recruitment status was Active, not recruiting

Sponsor:

Information provided by:

Asociación para Evitar la Ceguera en México

ClinicalTrials.gov Identifier:

NCT00599820

First received: June 30, 2006

Last updated: January 23, 2008

Last verified: January 2008

History of Changes

Tracking Information

First Received Date ^ICMJE

June 30, 2006

Last Updated Date

January 23, 2008

Start Date ^ICMJE

November 2005

Primary Completion Date

Not Provided

Current Primary Outcome Measures ^ICMJE

BCVA
Fluoresceine Angiography
Optical Coherence Tomography

Original Primary Outcome Measures ^ICMJE

Same as current

Change History

Complete list of historical versions of study NCT00599820 on ClinicalTrials.gov Archive Site

Current Secondary Outcome Measures ^ICMJE

Not Provided

Original Secondary Outcome Measures ^ICMJE

Not Provided

Current Other Outcome Measures ^ICMJE

Not Provided

Original Other Outcome Measures ^ICMJE

Not Provided

Descriptive Information

Brief Title ^ICMJE

Use of Intravitreal Bevacizumab in Eyes With Choroidal Neovascularization Secondary to Angioid Streaks

Official Title ^ICMJE

OCT, Visual Outcome and Angiographic Analysis of Choroidal Neovascularization in Six Eyes With Angioid Streaks Treated With a Single Intravitreal Injection of Bevacizumab

Brief Summary

Intravitreal Bevacizumab is an effective treatment for choroidal neovascularization secondary to Angioid Streaks

Detailed Description

A consecutive case series of patients with angioid streaks that developed subfoveal choroidal neovascularization were treated with a primary 2.5 mg injection of Bevacizumab (Avastin) intravitreally. All patients were evaluated with BCVA at 1, 2 , 4 and 12 weeks and OCT and fluoresceine angiography at month 1 and 3. (Patients will be follow 6 months)

Study Type ^ICMJE

Interventional

Study Phase

Phase 3

Study Design ^ICMJE

Allocation: Non-Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment

Condition ^ICMJE

Angioid Streaks
Choroidal Neovascularization

Intervention ^ICMJE

Drug: Intravitreal Bevacizumab

Study Arm (s)

Not Provided

Publications *

Not Provided

* Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.

Recruitment Information

Recruitment Status ^ICMJE

Active, not recruiting

Enrollment ^ICMJE

Not Provided

Completion Date

May 2006

Primary Completion Date

Not Provided

Eligibility Criteria ^ICMJE

Inclusion Criteria:

Clinical diagnosis of Angioid Streaks
Choroidal neovascularization associated
Untreated patients or patients treated once with PDT

Exclusion Criteria:

Ocular surgery excepting uncomplicated phacoemulsification
Glaucoma or any other ocular pathology

Gender

Both

Ages

Not Provided

Accepts Healthy Volunteers

Contacts ^ICMJE

Contact information is only displayed when the study is recruiting subjects

Location Countries ^ICMJE

Mexico

Administrative Information

NCT Number ^ICMJE

NCT00599820

Other Study ID Numbers ^ICMJE

APEC 010

Has Data Monitoring Committee

Not Provided

Responsible Party

Not Provided

Study Sponsor ^ICMJE

Asociación para Evitar la Ceguera en México

Collaborators ^ICMJE

Not Provided

Investigators ^ICMJE

Principal Investigator:	Adriana Solís-Vivanco, MD	Asociación para Evitar la Ceguera en México
Study Chair:	Jans Fromow-Guerra, MD PhD	Asociación para Evitar la Ceguera en México
Study Chair:	Mariana Martínez-Castellanos, MD	Asociación para Evitar la Ceguera en México
Study Chair:	Elizabeth Reyna-Castelán, MD	Asociación para Evitar la Ceguera en México
Study Chair:	Myriam Hernández-Rojas, MD	Asociación para Evitar la Ceguera en México
Study Chair:	Griselda Alvarez-Rivera, MD	Asociación para Evitar la Ceguera en México
Study Director:	Hugo Quiroz-Mercado, MD	Asociación para Evitar la Ceguera en México

Information Provided By

Asociación para Evitar la Ceguera en México

Verification Date

January 2008

^ICMJE Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP

To Top